RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024
Vishal Saundankar, Reiko Sato, Robyn Moucka, Pamela Smith, Kimbal Ford, Edward W Casey, Chris Barger, Richard Sheer, Brandon Suehs · 2026
Read RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024 by Vishal Saundankar, Reiko Sato, Robyn Moucka, Pamela Smith, Kimbal Ford, Edward W Casey, Chris Barger, Richard Sheer, Brandon Suehs (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13671429.txt.
Description
Vishal Saundankar and eight co-authors track RSV vaccine uptake among older adults in Medicare Advantage plans across the first two seasons of availability, in a two thousand twenty-six health services study. Federal recommendations for the respiratory syncytial virus vaccine began in two thousand twenty-three.
Uptake was higher in the first season than the second, peaking each October. Adults over seventy-five vaccinated more than those sixty-five to seventy-four, and high-risk groups led uptake. Still, among about 1.7 million people meeting two thousand twenty-four recommendations, roughly eighty percent had no record of vaccination. The authors call for targeted outreach to those at greatest risk of severe illness.
Catalog record
| CREATOR | Vishal Saundankar, Reiko Sato, Robyn Moucka, Pamela Smith, Kimbal Ford, Edward W Casey, Chris Barger, Richard Sheer, Brandon Suehs |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |